Stelara Patent Expiry in Europe
The primary patent protecting Stelara (ustekinumab) in Europe is set to expire in the coming years, opening the door for biosimilar competition. While specific dates can vary by country due to national patents and regulatory pathways, the key European patent is expected to expire around late 2023 or early 2024 in many major markets [1].
What Happens When Stelara's Patents Expire?
Once the core patents expire, it allows other pharmaceutical companies to develop and seek approval for biosimilar versions of Stelara. Biosimilars are highly similar to the original biologic drug in terms of safety, efficacy, and quality. Their introduction typically leads to increased competition and lower drug prices [2].
Can Biosimilars Enter Europe Before Patent Expiry?
While the main patent expiry is the primary trigger for biosimilar market entry, other factors can influence timelines. These include potential secondary patents, data exclusivity periods, and legal challenges. However, generally, biosimilar companies wait for key patent protections to lapse before launching their products [2].
How Does Stelara Compare to Other Biologics for Psoriasis?
Stelara is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and other inflammatory conditions. It works by targeting the IL-12 and IL-23 cytokines. Other biologics used for these conditions include TNF inhibitors (e.g., adalimumab, etanercept), IL-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., risankizumab, guselkumab). Each class of drug has a different mechanism of action and may be chosen based on a patient's specific condition, disease severity, and treatment history [3].
When Can Biosimilar Versions of Stelara Be Expected in Europe?
With the primary patent expiry anticipated soon, biosimilar versions of Stelara could begin to appear in European markets in the near future. DrugPatentWatch.com tracks patent expirations and provides detailed information on the intellectual property landscape for pharmaceuticals like Stelara [1]. The exact launch dates for specific biosimilars will depend on their individual development, approval processes, and any potential legal hurdles.
What Risks or Side Effects are Associated with Stelara?
Like all medications, Stelara carries potential risks and side effects. Common side effects can include upper respiratory infections, headache, fatigue, and injection site reactions. More serious but less common side effects may involve an increased risk of infections, including serious ones, and the potential for certain types of cancer. Patients should discuss any concerns with their healthcare provider [4].
Who Manufactures Stelara?
Stelara is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [5].
How Does Stelara's Patent Situation Differ in Other Regions?
Patent protection and expiry timelines can differ significantly between countries and regions. For example, patent expiry dates in the United States may not align with those in Europe. This is due to varying patent laws, regulatory environments, and the existence of different types of patent protections in each jurisdiction [1].
---
Sources:
[1] DrugPatentWatch.com
[2] https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471660/
[4] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/stelara-ustekinumab-information
[5] https://www.janssen.com/our-products